Skip to search formSkip to main contentSkip to account menu

Advate

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Antihemophilic Factor, Human RecombinantFactor VIII
Antihemophilic Factor, Human Recombinant 1 UNT Injection [Advate]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Preclinical Immunogenicity Assessment of Baxter‘s Longer-Acting FVIII Candidate BAX 855 Using Novel Preclinical Models,
Abstract 3323 Baxter is developing a PEGylated recombinant human factor VIII conjugate (BAX 855) based on the modification of… 
2007
2007
ReFacto® 1 and Advate® 2 : a single‐dose, randomized, two‐period crossover pharmacokinetics study in subjects with haemophilia A
Summary.  ReFacto is a recombinant B‐domain‐deleted, monoclonal antibody‐purified, solvent‐detergent‐treated factor VIII… 
2006
2006
ADVATE Inhibitor Risk Profile: 18 Months post-Licensure
By intention, there are similarities between ADVATE (ADVATE Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (r… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)